Meeting
2014 ASCO Annual Meeting
Patterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC).
Authors
Thomas Adam Abrams
Dana-Farber Cancer Institute, Boston, MA
Thomas Adam Abrams , Gary Meyer , Julie Moloney , Jeffrey A. Meyerhardt , Brian M. Wolpin , Deborah Schrag , Charles S. Fuchs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4131)
DOI
10.1200/jco.2014.32.15_suppl.4131
Abstract #
4131
Poster Bd #
218
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2017 Gastrointestinal Cancers Symposium
Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer.
First Author: Mark Ricigliano
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba
Poster
2020 Gastrointestinal Cancers Symposium
Real-world patterns of care among patients with metastatic pancreatic cancer (mPC).
First Author: Eileen Mary O'Reilly